

Hypoglycemics, Insulins Review

03/15/2010

Copyright © 2004 - 2010 by Provider Synergies, L.L.C. All rights reserved.
Printed in the United States of America.

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage and retrieval system without the express written consent of Provider Synergies, L.L.C.

All requests for permission should be mailed to:

*Attention: Copyright Administrator
Intellectual Property Department
Provider Synergies, L.L.C.
10101 Alliance Road, Ste 201
Cincinnati, Ohio 45242*

The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to PSTCReDitor@magellanhealth.com.



Together, we can do more.

Hypoglycemics, Insulins Review

FDA-Approved Indications^{1,2,3,4,5,6,7,8,9,10}

Drug	Types Available	Manufacturer	Indication(s)
human insulin (Humulin [®])	R, N, 70/30	Lilly	For the treatment of patients with diabetes mellitus for the control of hyperglycemia
human insulin (Novolin [®])	R, N, 70/30	Novo Nordisk	
insulin aspart (Novolog [®])	--	Novo Nordisk	To improve glycemic control in adults and children with diabetes mellitus
insulin aspart (Novolog [®] Mix)	70/30	Novo Nordisk	For the treatment of patients with diabetes mellitus for the control of hyperglycemia
insulin detemir (Levemir [®])	--	Novo Nordisk	For once or twice daily subcutaneous administration for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal insulin for the control of hyperglycemia
insulin glargine (Lantus [®])	--	Sanofi-Aventis	For once daily subcutaneous administration for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal insulin for the control of hyperglycemia
insulin glulisine (Apidra [™])	--	Sanofi-Aventis	To improve glycemic control in adults and children with diabetes mellitus
insulin lispro (Humalog [®])	--	Lilly	For the treatment of patients with diabetes mellitus for the control of hyperglycemia
insulin lispro (Humalog [®] Mix)	50/50, 75/25	Lilly	For the treatment of patients with diabetes mellitus for the control of hyperglycemia

Overview

It is estimated that 23.6 million Americans have diabetes mellitus.¹¹ Diabetes causes a significant economic burden to society in terms of both direct and indirect costs. Diabetes is also responsible for increased morbidity and mortality. Adequate glycemic control is crucial to minimize chronic complications including blindness, renal dysfunction resulting in dialysis or transplantation, and nontraumatic amputations.¹²

Previously, the American Diabetes Association (ADA) has not recommended use of hemoglobin A_{1c} levels (HbA_{1c}) in the diagnosis of diabetes due in part to a lack of standardization for the assay in the past. However, with HbA_{1c} assays now highly standardized so that results may be applied both temporally and uniformly across populations, the ADA has, with the 2010 update to Standards of Care in Diabetes, recommended use of the HbA_{1c} levels greater than or equal to 6.5 percent as the threshold for the diagnosis of diabetes.¹³

There are now multiple agents available for the treatment of diabetes when patients do not meet glycemic goals with oral antidiabetic agents. Insulin products are used as replacement therapy in the management of both type 1 and type 2 diabetes. Exogenous insulin supplements deficient levels of endogenous insulin, and temporarily restores the ability of the body to properly utilize carbohydrates, fats, and proteins.

The 2010 update to the American Diabetes Association (ADA) Consensus Algorithm reaffirms three steps in the treatment of type 2 diabetes. Consistent with prior editions of the algorithm, the first step is the initiation of metformin concurrent with lifestyle interventions at the time of diagnosis.^{14,15,16} If metformin therapy and lifestyle interventions fail to achieve or sustain glycemic goals, step two proposes the addition of either basal insulin or a sulfonylurea, other than glyburide. If step two recommendations are not successful in producing target glycemic goals, step three suggests adding or intensifying insulin therapy. When adding insulin to the regimen of a patient currently treated with a sulfonylurea, the sulfonylurea should be discontinued. For those patients who were started on basal insulin in step two, insulin intensification may include the addition of a rapid- or short-acting insulin. For type 2 diabetic patients with advanced stages of chronic kidney disease, the 2007 American Association of Clinical Endocrinologists Diabetes Mellitus Guidelines cites insulin as the therapeutic option of choice.¹⁷

Pharmacology

Insulin, secreted from the beta cells of the pancreas, lowers blood glucose levels by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting gluconeogenesis. Insulin also inhibits lipolysis in the adipocyte, inhibits proteolysis, and enhances protein synthesis. Exogenous insulin is derived from recombinant DNA technology with *E. coli* or yeast.

Pharmacokinetics

Comparison of Insulin Products

Type of Insulin	Drug	Composition of Insulin	Onset (hrs)	Peak (hrs)	Duration (hrs)	Compatibility for Mixing
Short-acting	Human insulin regular (Humulin R, Novolin R) ^{18,19}	Crystalline regular insulin is prepared by precipitation in the presence of zinc chloride at a neutral pH.	0.5-1	2-5	8-12	NPH
Rapid-acting	insulin aspart (Novolog) ²⁰	Consists of human insulin aspart in a clear aqueous solution. Created when the amino acid proline is substituted with aspartic acid at position B28.	0.17-0.33	1-3	3-5	NPH
	insulin glulisine (Apidra) ²¹	Created when the amino acid asparagine at position B3 is replaced by lysine and the lysine at position B29 is replaced by glutamic acid.	More rapid than regular insulin	0.92	0.9-2.6	NPH
	insulin lispro (Humalog) ²²	Consists of zinc-insulin lispro crystals dissolved in clear aqueous fluid. Created when the amino acids at positions 28 and 29 on the insulin B-chain are reversed.	More rapid than regular insulin	0.5-1.5	6-8	NPH
Rapid/Intermediate-acting combination products	insulin aspart (Novolog Mix) ²³	Suspension containing insulin aspart protamine crystals and soluble insulin aspart.	More rapid than regular insulin	1-4	Up to 24 hours	None
	insulin lispro (Humalog Mix) ^{24,25}	Suspension containing insulin lispro protamine suspension and insulin aspart injection.	More rapid than regular insulin	Earlier than regular insulin	Similar to corresponding Humulin mixes	None

Pharmacokinetics

Comparison of Insulin Products (continued)

Type of Insulin	Drug	Composition of Insulin	Onset (hrs)	Peak (hrs)	Duration (hrs)	Compatibility for Mixing
Intermediate-acting	human insulin NPH (Humulin N, Novolin N) ^{26,27}	Isophane (NPH) is modified, crystalline protamine zinc insulin. Its effects are comparable to a mixture of 2:1 to 3:1 regular insulin and protamine zinc insulin.	1-1.5	4-12	24	Regular, aspart, lispro, and glulisine
Long-acting	insulin detemir (Levemir) ^{28,29}	Created when the amino acid threonine in position B30 is omitted and a C14 fatty acid chain is added to amino acid B29	0.8-2.0	6-8 (maximum effect seen from 3-14 hours after dose)	5.7-23.2	None
	insulin glargine (Lantus) ³⁰	Created when the amino acids at position 21 of human insulin are replaced by glycine and two arginines are added to the C terminus of the B chain.	1.1	5 (no actual peak as insulin glargine is released slowly over 24 hours)	24 (only studied up to 24 hrs)	None

Contraindications/Warnings^{31,32,33,34,35,36,37,38,39,40}

Insulin is contraindicated during episodes of hypoglycemia.

Changes in insulin dosages should only be made under medical supervision.

Precautions

Insulin aspart (Novolog), insulin detemir (Levemir), insulin glulisine (Apidra), insulin glargine (Lantus), and insulin lispro (Humalog) contain cresol that has been reported to cause localized reactions and generalized myalgias. Insulin aspart (Novolog) and insulin glulisine contain approximately half the amount of cresol that insulin lispro contains.

Alkaline phosphatase elevations have been reported with human insulin aspart.

All insulins may require a dose adjustment for patients with renal impairment.

Drug Interactions^{41,42,43,44,45,46,47,48,49,50}

Beta-blockers and clonidine are commonly used drugs that may mask the signs and symptoms of hypoglycemia.

Substances that may decrease insulin requirements include oral antidiabetic agents, monoamine oxidase inhibitors (MAOIs), ACE inhibitors, alcohol, sulfonamide antibiotics, nonselective beta-blockers, and alpha-adrenergic blockers.

Substances that may increase insulin requirements include oral contraceptives, thiazides, glucocorticoids, growth hormone, and thyroid hormones.

Adverse Effects^{51,52,53,54,55,56,57,58,59,60}

The most common adverse effect of all insulin products is hypoglycemia. Glucose monitoring is recommended in all diabetic patients. Injection site reactions can occur with any type of injectable insulin. Other possible adverse effects of the injectable insulins include lipodystrophy, pruritis, and rash.

In clinical trials, insulin glargine (Lantus) had treatment-emergent injection site pain in 2.7 percent of patients versus 0.7 percent of patients on NPH insulin. Treatment discontinuation was not required. Insulin detemir (Levemir) was associated with more frequent mild injection site reactions than with insulin NPH.

Adverse effects data are obtained from prescribing information and therefore, should not be considered comparative or all-inclusive.

Special Populations^{61,62,63,64,65,66,67,68,69,70}

Pediatrics

Human insulin (Humulin, Novolin) products have been used in all age groups. Human insulin lispro (Humalog) can be used in children greater than three years of age, and human insulin aspart (Novolog) can be given to pediatric patients over the age of two years. Insulin glulisine (Apidra) is approved for use in pediatric patients with type 1 diabetes from four to 17 years of age. The safety and efficacy of insulin NPH combinations with insulin aspart and insulin lispro in children have not been evaluated by the FDA, and little data exist. Insulin glargine (Lantus) is approved for use in type 1 diabetic children from six to 15 years of age; insulin detemir (Levemir) is approved for type 1 diabetes in pediatric patients as well, with pharmacokinetic data in patients as young as six years. In general, intermediate and long-acting insulins can have slightly higher area-under-the-curves and maximum concentrations in children.

In one multicenter, open-label, randomized, six-month study, 349 type 1 diabetes mellitus patients aged five to 16 years received insulin glargine once daily or NPH insulin either once or twice daily.⁷¹ Fasting blood glucose (FBG) levels decreased significantly more in the insulin glargine group (-1.29 mmol/L) than in the NPH insulin group (-0.68 mmol/L, p=0.02). The percentage of symptomatic hypoglycemic events was similar between groups; however, fewer patients in the insulin glargine group reported severe hypoglycemia (23 versus 29 percent, respectively) and severe nocturnal hypoglycemia (13 versus 18 percent, respectively), although these differences were not statistically significant. Fewer serious adverse events occurred in the insulin glargine group than in the NPH insulin group (p<0.02).

The clinical efficacy and safety of two treatment regimens (biphasic insulin aspart at all three meals plus NPH insulin at bedtime versus premixed human insulin at breakfast and regular insulin at lunch and dinner, with NPH at bedtime) were compared in 167 adolescents with type 1 diabetes.⁷² The multinational, randomized, open-label, parallel-group trial was four months in duration. HbA_{1c} after four months on biphasic insulin aspart (9.39 percent) was not significantly different from that with human insulin (9.30 percent). The body mass index increased in both groups, but significantly ($p=0.005$) less in the biphasic insulin aspart group. No significant group differences were found for the rate of hypoglycemic episodes.

In a 26-week, open-label, randomized, parallel-group study, 347 children with type 1 diabetes, aged six to 17 years, received insulin detemir or NPH insulin once or twice daily plus insulin aspart before meals.⁷³ The mean HbA_{1c} decreased by approximately 0.8 percent with both treatments. Within-subject variation in self-measured fasting plasma glucose was significantly lower with insulin detemir than with NPH insulin ($p<0.001$), as was mean fasting plasma glucose (8.4 versus 9.6 mmol/L, $p=0.022$). The risk of nocturnal hypoglycemia was 26 percent lower with insulin detemir ($p=0.041$).

In an effort to compare the safety and efficacy of insulin glulisine to that of insulin lispro in children and adolescents with type 1 diabetes, 572 patients aged four years and older were randomized to receive either insulin glulisine or insulin lispro, administered subcutaneously within 15 minutes before a meal, in an open-label, active-controlled, non-inferiority trial.⁷⁴ During this 26-week study, patients also received insulin glargine (administered once daily in the evening) or NPH insulin (administered once in the morning and once in the evening). There were no significant differences observed between the two treatment groups with respect to glycemic control.

Pregnancy

The human insulins, insulin aspart, and insulin lispro are Pregnancy Category B. Insulin detemir, insulin glargine, and insulin glulisine are Pregnancy Category C.

In 322 pregnant women with type 1 diabetes, meal-time regular insulin or insulin aspart was administered in an open-label, parallel-group, multicenter study.⁷⁵ Patients had HbA_{1c} ≤ 8 percent at confirmation of pregnancy, and insulin doses were titrated toward predefined glucose targets and HbA_{1c} < 6.5 percent. Major hypoglycemia occurred at a rate of 1.4 versus 2.1 episodes/year-exposure with insulin aspart and regular insulin, respectively (relative risk 0.72 [95% CI, 0.36-1.46]). The risk of major nocturnal hypoglycemia was 52 percent (RR 0.48 [0.20-1.143]) lower with insulin aspart compared with regular insulin. The HbA_{1c} for insulin aspart patients was comparable with human insulin in second and third trimesters, and a total of 80 percent of subjects achieved HbA_{1c} ≤ 6.5 percent. Maternal safety profiles and pregnancy outcomes were similar between treatments.

Renal impairment

Renally impaired patients are subject to increased levels of circulating insulin. Dose adjustments may be warranted in this patient population.

Ethnicity

In an open-label, randomized, parallel, multinational, 24-week, non-inferiority study, 443 Asian patients with type 2 diabetes received either insulin glargine (Lantus) daily or NPH insulin at bedtime, in addition to oral glimepiride.⁷⁶ HbA_{1c} levels decreased in the insulin glargine and

NPH groups over the study period (-0.99 versus -0.77 percent; $p=0.03$). The number of hypoglycemic episodes was significantly lower with insulin glargine compared to NPH insulin ($p<0.004$), including severe ($p<0.03$) and nocturnal ($p<0.001$) cases.

A six-month multicenter, open-label, randomized trial in Japan enrolled 160 patients with type 2 diabetes mellitus.⁷⁷ Patients were assigned to one of two groups: those who received twice daily injections of biphasic insulin aspart (Novolog Mix) and those on injections of insulin aspart (Novolog) three times daily with or without multiple daily injections of NPH insulin. At six months, HbA_{1c} decreased by approximately 2.5 percent in both groups. No incidence of major hypoglycemia was observed in either regimen.

A 24-week, multi-center, open-label, randomized, parallel trial randomized 192 Western Pacific patients to biphasic insulin aspart (Novolog Mix) treatment once daily at dinnertime or continuation of oral antidiabetic therapy.⁷⁸ Those not reaching treatment targets on biphasic insulin aspart were switched to twice daily administration at week 14 ($n=50$). Significantly greater reductions in HbA_{1c} were seen with once and twice daily biphasic insulin aspart versus oral therapy (1.24 versus 1.34 versus 0.67 percent; $p<0.01$). Hypoglycemic episodes were reported in 54 percent of the patients taking biphasic insulin aspart and 30 percent of the patients taking oral antidiabetic agents.

Other

For categories as age, gender, obesity, and hepatic impairment, there are no significant data that suggest a difference in drug effect in these patients.

Dosages^{79,80,81,82,83,84,85,86,87,88}

Drug	Dosing	Time of administration related to mealtime	Availability
human insulin (Humulin, Novolin)	Dosing should be titrated to glycemic control in combination with an intermediate or long acting insulin (and/or with oral antidiabetic agents for type 2 diabetics)	30-60 minutes prior to meal	10 mL vials, Humulin 500 units/mL 20 mL vials 3 mL prefilled pen (Humulin N, 70/30)
insulin aspart (Novolog)		5-10 minutes before eating	10 mL vial, 3 mL PenFill cartridge, 3 mL prefilled FlexPen
insulin glulisine (Apidra)		Within 15 minutes before a meal or within 20 minutes after starting a meal	10 mL vial, 3 mL cartridge, 3 mL prefilled SoloStar pen
insulin lispro (Humalog)		No more than 15 minutes before a meal or immediately after a meal	10 mL vial, 3 mL vial, 3 mL cartridge, 3 mL prefilled KwikPen, 3 mL prefilled pen
insulin aspart/protamine aspart (Novolog Mix)	Dosing should be titrated to glycemic control	Dosed within 15 minutes of meal initiation twice daily before breakfast and supper	10 mL vial, 3 mL prefilled FlexPen
insulin lispro/protamine lispro (Humalog Mix)			10 mL vial, 3 mL prefilled KwikPen
insulin detemir (Levemir)	0.1-0.2 units/kg once daily or 10 units once or twice daily	Once daily in the evening or twice daily	10 mL vial, 3 mL prefilled FlexPen
insulin glargine (Lantus)	Dosing should be individualized based on the type of diabetes and whether the patient is insulin-naive	Once daily at anytime during the day	10 mL vial, 3 mL cartridge for Opticlick, 3 mL prefilled SoloStar pen

Regular insulin, insulin glulisine (Apidra), and insulin aspart (Novolog) can be administered intravenously.

Doses of insulin should be individualized. Generally, for both children and adults, an initial dose is 0.5 to 1 unit/kg/day. Insulin requirements may be altered during intercurrent conditions such as illness, emotional disturbances, or stress.

All of the insulin products are available in cartridge and/or pen delivery systems. The FlexPen delivery system was redesigned and launched in a prefilled pen for insulin detemir (Levemir), insulin aspart, and insulin aspart/protamine aspart (Novolog Mix).⁸⁹ The new design requires 30 percent less injection force than the original pen device, and does not allow patients to dial a dose of insulin larger than the amount of insulin remaining in the pen. The new design also has enhanced color branding with color-coded cartridge holders for easy identification and differentiation of rapid- and long-acting insulin products. The FlexPen is able to dial up to 60 units of insulin in one-unit increments.

For patients that may require smaller doses of insulin (e.g., children), there are two reusable pen devices currently available. The HumaPen[®] LUXURA[™] HD allows patients to dial insulin in

half-unit increments (from one to 30 units), and it should only be used with insulin lispro (Humalog) cartridges.⁹⁰ The NovoPen[®] Junior can dial half-unit increments (from one to 35 units), and it should only be used with the Novo Nordisk product line of insulin cartridges.⁹¹

The SoloStar[®] prefilled pen devices for insulin glargine (Lantus) and insulin glulisine (Apidra) are useful for patients that require larger doses of insulin.^{92,93} This pen system is able to dial up to 80 units of insulin in one-unit increments. Patients can dial up to 60 units of insulin in one-unit increments with the HumaPen MEMOIR[™] for insulin lispro. The HumaPen MEMOIR is also a reusable insulin pen device that stores up to the last 16 insulin doses (including priming doses). Patients can track the date, time, and amount of these doses.⁹⁴

Most cartridges and pens are refrigerated before use. Following the first use, these formulations should be stored at room temperature. Expiration dates are typically 10-14 days for regular insulin and insulin NPH, as well as mixes of regular insulin, insulin aspart, or insulin lispro with insulin NPH. The rapid-acting insulins and insulin glargine cartridges and pens expire in 28 days, while those for insulin detemir last 42 days.

Clinical Trials

Search Strategies

Studies were identified through searches performed on PubMed and review of information sent by manufacturers. Search strategy included the FDA-approved use of all brand names in this class. Randomized, comparative, controlled trials comparing agents within this class in an outpatient setting for the approved indications are considered the most relevant in this category. Studies included for analysis in the review were published in English, performed with human participants and randomly allocated participants to comparison groups. In addition, studies must contain clearly stated, predetermined outcome measure(s) of known or probable clinical importance, use data analysis techniques consistent with the study question and include follow-up (endpoint assessment) of at least 80 percent of participants entering the investigation. Despite some inherent bias found in all studies, including those sponsored and/or funded by pharmaceutical manufacturers, the studies in this therapeutic class review were determined to have results or conclusions that do not suggest systematic error in their experimental study design. While the potential influence of manufacturer sponsorship/funding must be considered, the studies in this review have also been evaluated for validity and importance.

Numerous studies were found meeting standard criteria. The data included here were further evaluated to remove studies that were found to be unacceptable for the following reasons: small treatment group, post hoc analysis, use of insulin pumps, studies relying on outcomes from self-reported data, inappropriate treatment duration, and unapproved formulation, dosage regimen, or route of administration.

The method of administration and associated monitoring makes it difficult to perform properly blinded studies with these drugs. Due to the lack of double-blind studies, open-label studies have been included; while these large studies may produce accurate results, the study design should be taken into consideration.

In countries outside of the US, blood glucose values are typically reported in mmol/L. For those studies reporting blood glucose values in mmol/L, the value in mg/dL can be estimated by multiplying the mmol/L value by 18.

insulin aspart (Novolog) and regular human insulin

A prospective, multicenter, randomized, parallel-group, open-label study was performed in 423 patients with type 1 diabetes.⁹⁵ Main outcome measures included blood glucose control assessed by HbA_{1c}, nine-point self-monitored blood glucose profiles, insulin dose, quality of life, hypoglycemia, and adverse events. After 12 weeks of treatment, HbA_{1c} was significantly lower in the insulin aspart group compared to regular human insulin subjects by 0.17 percent (95% CI, 0.30-0.04, $p < 0.05$). Comparison of the blood glucose profiles showed lower blood glucose levels with insulin aspart after breakfast and dinner. There were no differences between treatments in the incidence of hypoglycemic episodes or in the adverse event profiles. The WHO Diabetes Treatment Satisfaction Questionnaire score for perceived hyperglycemia was lower with insulin aspart ($p = 0.005$), and patients found the insulin aspart treatment more flexible ($p = 0.022$).

In a six-month, similarly designed trial in 1,070 adults with type 1 diabetes, HbA_{1c} was significantly lower in the insulin aspart group (0.12 percent reduction in HbA_{1c}) after six months.⁹⁶ The insulin aspart group had lower post-prandial blood glucose levels but had higher preprandial glucose levels before breakfast and dinner. Patients were more satisfied with insulin aspart than with regular insulin. Hypoglycemia episodes overall were similar in both treatment groups, but major hypoglycemia episodes occurring at night that required parenteral treatment occurred more often in the regular insulin group.

Another similarly designed study was performed over six months with a six-month extension period. In 882 men and women with type 1 diabetes, HbA_{1c} values were significantly lower with insulin aspart than with regular insulin (7.78 versus 7.93 percent; $p = 0.005$) at six months.⁹⁷ The difference in HbA_{1c} continued to remain significant at 12 months. The mean basal NPH dose at 12 months was significantly higher for the insulin aspart group than that for the regular insulin group (0.314 versus 0.296 units/kg; $p = 0.011$). A similar percentage of patients in each treatment group had a major hypoglycemic episode by six months. Fewer subjects in the insulin aspart group than in the regular insulin group (four versus eight percent) experienced a major hypoglycemic episode during the night.

A trial was conducted in patients with type 1 diabetes who were randomized to mealtime insulin aspart with up to four daily NPH doses and a 25 percent increase in bedtime NPH dose ($n = 187$) or to mealtime human unmodified insulin with once or twice daily basal NPH insulin ($n = 181$).⁹⁸ Efficacy and safety were evaluated at 12 weeks (primary evaluation period) and 64 weeks. At 12 and 64 weeks, there was no statistically significant difference in HbA_{1c} reduction between the insulin aspart and regular insulin groups (-0.09 and -0.14 percent, respectively). Post-prandial glucose values were lower with insulin aspart, and no significant differences were found in mild or severe hypoglycemia or adverse event rates. At 64 weeks, treatment satisfaction was higher in the insulin aspart group while quality of life was not different.

To compare quality of life (QOL) and treatment satisfaction, 424 patients were randomized to basal-bolus treatment with either insulin aspart ($n = 283$) or regular human insulin ($n = 141$) in the six-month, multinational, randomized, open-label trial.⁹⁹ After six months, insulin aspart was associated with significantly greater improvement in treatment satisfaction than human insulin in two different scales ($p < 0.01$), and in QOL with respect to diet restrictions ($p < 0.01$). Improved satisfaction was mainly due to increased dietary and leisure time flexibility ($p < 0.0001$).

In the multinational, double-blind, crossover trial, 155 patients with type 1 diabetes were randomized to two 16-week treatment periods on either insulin aspart or human insulin.¹⁰⁰ NPH

insulin was given as basal insulin once or twice daily as needed. Treatment periods were separated by a four-week washout. The rate of major nocturnal hypoglycemic episodes was 72 percent lower with insulin aspart than with human insulin (0.067 versus 0.225 events/month; $p=0.001$). The total rate of major hypoglycemia did not differ significantly between treatments (insulin aspart/human insulin relative risk 0.72; 95% CI, 0.47-1.09, $p=0.12$). Mean HbA_{1c} remained constant, slightly below 7.7 percent on both treatments.

A total of 231 type 2 diabetic patients were randomized to insulin aspart ($n=75$), regular insulin ($n=80$), or insulin 70/30 ($n=76$) for three months with or without bedtime NPH insulin.¹⁰¹ A total of 204 patients completed the trial according to protocol. The primary endpoint was change in HbA_{1c} from baseline. HbA_{1c} decreased 0.91 ± 1.00 percent for insulin aspart, 0.73 ± 0.87 percent for regular insulin, and 0.65 ± 1.10 percent for insulin 70/30. Postprandial blood glucose decreased more in the insulin aspart group compared with regular insulin and insulin 70/30. Hypoglycemic events per month were 0.56 with regular insulin, 0.40 with insulin aspart, and 0.19 with insulin 70/30.

biphasic insulin aspart (Novolog Mix 70/30) and human insulin 70/30

In a randomized, open-label, parallel trial, 177 patients with type 2 diabetes were assigned to meal-related injection of biphasic insulin aspart three times a day or biphasic human insulin twice a day over a study period of 24 weeks.¹⁰² The mean difference between treatment groups in HbA_{1c} after 24 weeks of treatment was 0.08 percent ($p=0.6419$). Significant differences in blood glucose levels were observed after lunch (156 versus 176 mg/dL, $p=0.0289$), before dinner (142 versus 166 mg/dL $p=0.006$), and after dinner (154 versus 182 mg/dL $p=0.002$) in favor of biphasic insulin aspart. No differences were found regarding safety parameters in the two treatment groups.

biphasic insulin aspart (Novolog Mix 70/30) and NPH human insulin

In the double-blind study of 403 patients with type 2 diabetes not controlled on oral hypoglycemic agents, patients were randomized to receive either biphasic insulin aspart or NPH insulin immediately before breakfast and dinner for 16 weeks.¹⁰³ Oral hypoglycemic agents were discontinued. In both groups, HbA_{1c} decreased by greater than 0.6 percent ($p<0.0001$ versus baseline). The biphasic insulin aspart group had a decreased daily postprandial glycemic exposure (mean difference 0.69 mmol/L; $p<0.0001$). Overall safety profile of both groups was similar.

biphasic insulin aspart (Novolog Mix 70/30) and biphasic insulin lispro (Humalog Mix 75/25)

Patients ($n=137$) with type 2 diabetes mellitus currently receiving insulin treatment were randomized to a multicenter, open-label, crossover comparison of biphasic insulin aspart and biphasic insulin lispro.¹⁰⁴ Efficacy and safety profiles were assessed after 12 weeks of treatment. Treatment with biphasic insulin aspart was not inferior to treatment with biphasic insulin lispro. Adverse event profiles were similar between treatments, as was the incidence of hypoglycemic episodes (0.69 episodes/month with biphasic insulin aspart and 0.62 episodes/month with biphasic insulin lispro, $p=NS$). For all device features assessed, the biphasic insulin aspart FlexPen consistently received higher scores (all $p<0.005$). Furthermore, 74.6 percent of patients preferred to continue using the FlexPen, whereas 14.3 percent preferred the biphasic insulin lispro pen ($p<0.001$).

insulin detemir (Levemir) and insulin NPH (Novolin N)

A six-month, prospective, randomized, open-label, controlled, parallel-group trial conducted at 92 sites included 749 men and women with type 1 diabetes with HbA_{1c} < 12 percent who were already taking daily intermediate- or long-acting insulin and a fast-acting human insulin or insulin analogue as bolus insulin.¹⁰⁵ Patients were randomized to insulin detemir or NPH at bedtime in combination with human insulin with main meals. Main outcome measures included HbA_{1c}, FPG, and hypoglycemia. After six months, FPG was lower with insulin detemir than with NPH (-1.16 mmol/L difference; p=0.001), whereas HbA_{1c} did not differ significantly between treatments (-0.12 percent; p=NS). Day-to-day variability in self-measured fasting blood glucose was lower with insulin detemir (2.82 versus 3.60 mmol/L; p<0.001). Lower glucose levels were seen before breakfast with insulin detemir compared to NPH (p<0.001). There was a 26 percent reduction in the relative risk of nocturnal hypoglycemia with insulin detemir compared with NPH (p=0.003). The adverse effect profiles were similar between treatment groups.

In the 20-week, multicenter, randomized, open-label, parallel-group trial, 504 type 2 diabetic patients were randomly assigned to receive an evening SC injection of insulin detemir, a pre-breakfast injection of insulin detemir, or an evening injection of NPH insulin.¹⁰⁶ Morning and evening detemir were associated with reductions in HbA_{1c} similar to those receiving evening NPH (-1.58, -1.48, and -1.74 percent, respectively). Compared with evening NPH, 24-hour and nocturnal hypoglycemia were reduced by 53 percent (p=0.019) and 65 percent (p=0.031), respectively, with evening insulin detemir. Incidences of hypoglycemia did not differ significantly between groups that received morning and evening insulin detemir, but nocturnal hypoglycemia was reduced further, by 87 percent, with morning insulin detemir compared with evening NPH (p<0.001). Weight gain was 1.2, 0.7, and 1.6 kg with morning insulin detemir, evening insulin detemir, and NPH, respectively (p=0.005 for evening detemir versus NPH).

Patients with type 2 diabetes (n=476) with HbA_{1c} 7.5-10.0 percent were randomized to the addition of insulin detemir or NPH insulin twice daily to existing oral antidiabetic agent therapy in a parallel-group, open-label, multicenter trial.¹⁰⁷ At 24 weeks, HbA_{1c} had decreased by 1.8 and 1.9 percent for insulin detemir and NPH insulin, respectively (p=NS). In both groups, 70 percent of participants achieved an HbA_{1c}≤7.0, but the proportion achieving this without hypoglycemia was higher with insulin detemir than with NPH insulin (26 versus 16 percent, p=0.008). Compared with NPH insulin, the risk for all hypoglycemia with insulin detemir was reduced by 47 percent (p<0.001) and nocturnal hypoglycemia by 55 percent (p<0.001). The mean weight gain was 1.2 kg with insulin detemir and 2.8 kg with NPH insulin (p<0.001).

insulin detemir (Levemir), insulin aspart (Novolog), and biphasic insulin aspart (Novolog Mix 70/30)

In an open-label, controlled, multicenter trial, 708 patients who were receiving maximally tolerated doses of metformin and sulfonylurea were randomly assigned to receive biphasic insulin aspart twice daily, insulin aspart three times daily, or insulin detemir once daily (twice if necessary).¹⁰⁸ Outcome measures at one year were HbA_{1c}, the proportion of patients with a HbA_{1c} of 6.5 percent or less, the rate of hypoglycemia, and weight gain. At one year, HbA_{1c} was similar in the biphasic group and the insulin aspart group (7.3 versus 7.2 percent, respectively; p=0.08), but higher in the basal group (7.6 percent, p<0.001 for both comparisons). The respective proportions of patients with a HbA_{1c}≤6.5 percent were 17.0, 23.9, and 8.1 percent; respective mean numbers of hypoglycemic events per patient per year were 5.7, 12.0, and 2.3 percent; and respective mean weight gains were 4.7 kg, 5.7 kg, and 1.9 kg. Rates of adverse events were similar among the three groups.

insulin detemir (Levemir), insulin NPH (Novolin N), and insulin aspart (Novolog)

The study was an open-label, parallel-group comparison conducted at 46 centers in five countries and included 448 patients with type 1 diabetes. Patients were randomized to insulin detemir or NPH insulin. Insulin aspart was given to both groups at meals.¹⁰⁹ After six months, comparable HbA_{1c} levels were found between the two treatment groups. FPG was lower in patients treated with insulin detemir (-0.76 mmol/L), but this difference was not statistically significant (p=0.097). Within-subject variation of self-measured FPG was lower with insulin detemir than with NPH insulin (3.37 versus 3.78 mmol/L, p<0.001). Risk of hypoglycemia was 22 percent lower with insulin detemir than with NPH insulin (p<0.05) and 34 percent lower for nocturnal hypoglycemia (p<0.005). Nightly plasma glucose profiles were smoother and more stable with insulin detemir (p=0.05). Body weight was significantly lower with insulin detemir at the end of the trial (p<0.001).

Patients with type 1 diabetes (n=408) were randomized in a 16-week, open-label, parallel-group trial to insulin detemir administered twice daily either before breakfast and at bedtime or at a 12-hour interval or NPH insulin administered before breakfast and at bedtime.¹¹⁰ Insulin aspart was the mealtime insulin. With both insulin detemir groups, before breakfast and at bedtime or at a 12-hour interval, FPG was lower than with NPH insulin (-1.5 mmol/L, p=0.004; -2.3 mmol/L, p<0.001, respectively), as was self-measured pre-breakfast plasma glucose (p=0.006 and p=0.004, respectively). The risk of minor hypoglycemia was lower in both insulin detemir groups (25 percent, p=0.046; 32 percent, p=0.002; respectively) compared with NPH insulin in the last 12 weeks of treatment. Although HbA_{1c} for each insulin detemir group was not different from the NPH group at endpoint, HbA_{1c} for the pooled insulin detemir groups was significantly lower than the NPH group (mean difference -0.18 percent; p=0.027). Within-person between-day variation of self-measured pre-breakfast plasma glucose was lower for both detemir groups (both p<0.001). The NPH group gained weight during the study, but there was no clinically significant change in weight in either of the insulin detemir groups (-0.8 kg, p=0.006; -0.6 kg, p=0.040, respectively).

A multinational, open-label, parallel-group trial studied 505 patients with type 2 diabetes.¹¹¹ Patients were randomized to insulin detemir or NPH, receiving basal insulin either once or twice daily, and insulin aspart at mealtimes. After 26 weeks of treatment, significant reductions in HbA_{1c} were observed for insulin detemir (p=0.004) and NPH (p=0.0001), resulting in comparable levels at study end (insulin detemir, 7.6 percent; NPH insulin, 7.5 percent). The number of basal insulin injections administered per day had no effect on HbA_{1c} levels (p=0.50). At study end, FPG concentrations were similar for the two treatment groups (p=0.66), as were reductions in FPG (insulin detemir, 0.5 mmol/L; NPH insulin, 0.6 mmol/L). However, within-subject day-to-day variation in fasting FPG was significantly lower with insulin detemir (p=0.021). The frequency of adverse events and the risk of hypoglycemia were comparable for the two treatment groups.

The multinational, 16-week, open-label, parallel-group trial included 400 people with type 1 diabetes randomized to insulin detemir in the morning and before dinner or morning and bedtime, or to NPH morning and bedtime, all in combination with mealtime insulin aspart.¹¹² HbA_{1c} was comparable among the three groups after 16 weeks, with reductions of 0.39-0.49 percent (p=0.64). Lower FPG was observed with insulin detemir morning/dinner and insulin detemir morning/bedtime compared with NPH groups (9.8 and 9.1 versus 11.1 mmol/L, p=0.006), but the insulin detemir groups did not differ significantly (p=0.15). Within-person variation in self-measured FPG was significantly lower for both insulin detemir regimens than for NPH (SD: insulin detemir morning/dinner 2.5, insulin detemir morning/bedtime 2.6, NPH 3.1

mmol/L, $p < 0.001$) but was comparable between the two insulin detemir groups ($p = 0.48$). Ten-point plasma glucose profiles were lower between dinner and breakfast in the insulin detemir morning/dinner group ($p = 0.043$) compared with the two other groups. Risk of overall and nocturnal hypoglycemia was similar for the three groups.

insulin detemir (Levemir), insulin NPH (Novolin N), insulin aspart (Novolog), and regular insulin (Novolin R)

In the 18-week, randomized, open-label, parallel trial, 595 patients with type 1 diabetes received insulin detemir or NPH insulin in the morning and at bedtime in combination with mealtime insulin aspart or regular human insulin, respectively.¹¹³ Glycemic control with insulin detemir/insulin aspart was improved in comparison with NPH insulin/regular human insulin (HbA_{1c}: 7.88 versus 8.11 percent; $p < 0.001$). Lower postprandial plasma glucose levels were seen in the insulin detemir/insulin aspart group ($p < 0.001$), as well as lower within-person day-to-day variation in plasma glucose (SD: 2.88 versus 3.12 mmol/L; $p < 0.001$). Risk of overall and nocturnal hypoglycemia was 21 percent ($p = 0.036$) and 55 percent ($p < 0.001$) lower in the insulin detemir/insulin aspart group than in the NPH insulin/regular human insulin group, respectively.

A 22-week, multinational, open-label, randomized, parallel-group trial enrolled 395 patients with type 2 diabetes. Patients were randomized to treatment with either insulin detemir in combination with insulin aspart at meals or insulin NPH in combination with regular human insulin at meals.¹¹⁴ Basal insulins were administered either once or twice daily. At 22 weeks, HbA_{1c} was comparable between treatments (insulin detemir group: 7.46 percent, NPH group: 7.52 percent, $p = 0.515$) with decreases from baseline of 0.65 and 0.58 percent, respectively. The insulin detemir group was associated with a significantly lower within-person variation in self-measured FPG (SD: 1.20 versus 1.54 mmol/L, $p < 0.001$), as well as a lower body weight gain (0.51 versus 1.13 kg, $p = 0.038$) than with the NPH group. The risk of nocturnal hypoglycemia was 38 percent lower with the insulin detemir group compared to the NPH group ($p = 0.14$). The overall safety profile was similar between the two treatments.

insulin glargine (Lantus) and NPH human insulin

In an open-label study to determine the safety and efficacy of insulin glargine in type 1 diabetics, patients were randomized to receive insulin glargine once daily ($n = 310$) or NPH insulin ($n = 309$) with intermittent insulin lispro over 16 weeks.¹¹⁵ NPH insulin patients maintained their regimen of either once daily or twice daily injections whereas insulin glargine patients received once daily injections at bedtime. Insulin glargine patients had lower self-reported fasting blood glucose concentrations. More patients achieved a fasting blood glucose concentration of less than 119 mg/dL in the insulin glargine group (29.6 percent) than in the NPH insulin group (16.8 percent). No differences were noted in the HbA_{1c} or hypoglycemic episodes between the groups. Less variability of blood glucose concentrations was noted in the insulin glargine group. More injection site pain was reported in the insulin glargine group (6.1 percent) than in the NPH group (0.3 percent).

In a multicenter, randomized, parallel-group study, 534 type 1 diabetics were randomized to receive premeal regular insulin and either daily insulin glargine or NPH insulin (once or twice daily) for up to 28 weeks.¹¹⁶ A small decrease in HbA_{1c} levels was noted with both insulin glargine (-0.16 percent) and NPH insulin (-0.21 percent; $p > 0.05$). Significant reductions in median FPG levels from baseline (-1.67 versus -0.33 mmol/L with NPH insulin, $p = 0.0145$) were achieved with insulin glargine. After the one-month titration phase, significantly fewer subjects receiving insulin glargine experienced symptomatic hypoglycemia (39.9 versus 49.2 percent,

p=0.0219) or nocturnal hypoglycemia (18.2 versus 27.1 percent, p=0.0116) compared with subjects receiving NPH insulin.

Patients with type 1 diabetes were treated for up to 28 weeks with insulin glargine (n=199) or NPH insulin (n=195) in addition to preprandial regular insulin in a randomized, parallel-group study.¹¹⁷ A greater mean decrease in FBG was achieved at endpoint with insulin glargine compared with NPH insulin (-21 versus -10 mg/dL; p=0.015), and a greater percentage of patients treated with insulin glargine reached the target FBG (32.6 versus 21.3 percent; p=0.015). Similar percentages of patients in both treatment groups achieved HbA_{1c} values of 7 percent or less at endpoint. After the one-month titration phase, the percentage of patients who reported at least one symptomatic hypoglycemic event confirmed by a blood glucose value of less than 50 mg/dL was significantly lower with insulin glargine than with NPH insulin (73.3 versus 81.7 percent; p=0.021). Severe hypoglycemia was also significantly reduced in insulin glargine patients.

One hundred and twenty-one patients with type 1 diabetes mellitus on four times a day NPH and lispro insulin at each meal were randomized to either continuation of NPH four times a day (n=60) or once daily insulin glargine at dinnertime (n=61) for one year.¹¹⁸ Lispro insulin at meal-time was continued in both groups. Mean daily blood glucose was lower with insulin glargine (p<0.05). HbA_{1c} at four months did not change with NPH but decreased with insulin glargine from 7.1 to 6.7 percent, and remained lower than NPH at 12 months (6.6 percent, p<0.05 versus NPH). The frequency of mild hypoglycemia was lower with insulin glargine versus NPH (7.2 versus 13.2 episodes/patient-month, p<0.05). After one year, NPH treatment resulted in no change of responses to hypoglycemia, while plasma glucose, thresholds and maximal responses of plasma adrenaline and symptoms to hypoglycemia improved with insulin glargine (p<0.05).

In an open-label, 24-week, multicenter trial, 765 patients with type 2 diabetes on one or two oral medications with inadequate glycemic control (HbA_{1c} > 7.5 percent) were randomized to either bedtime insulin glargine or NPH and also continued their prestudy medications.¹¹⁹ Mean FPG at end point was similar with insulin glargine and NPH (117 versus 120 mg/dL), as was HbA_{1c} (6.96 versus 6.97 percent). A majority of patients (approximately 60 percent) attained HbA_{1c} less than 7 percent with each insulin type. However, nearly 25 percent more patients attained this without documented nocturnal hypoglycemia (\leq 72 mg/dL) with insulin glargine (33.2 versus 26.7 percent, p<0.05). Rates of other categories of symptomatic hypoglycemia were 21 to 48 percent lower with insulin glargine.

A total of 518 type 2 diabetics who were receiving NPH insulin with or without regular insulin for postprandial control were randomized to receive insulin glargine once daily (n=259) or NPH insulin once or twice daily (n=259) for 28 weeks in an open-label, multicenter trial.¹²⁰ The treatment groups showed similar improvements in HbA_{1c} from baseline to end point on intent-to-treat analysis. The mean change in HbA_{1c} from baseline to endpoint was similar in the insulin glargine group (-0.41 \pm 0.1 percent) and the NPH group (-0.59 \pm 0.1 percent). The treatments were associated with similar reductions in fasting glucose levels. Overall, mild symptomatic hypoglycemia was similar in insulin glargine subjects (61.4 percent) and NPH insulin subjects (66 percent). However, nocturnal hypoglycemia in the insulin glargine group was reduced by 25 percent during the treatment period after the dose-titration phase compared to 35.5 percent for NPH patients (p=0.0136). Patients in the insulin glargine group experienced less weight gain than those in the NPH group (0.4 versus 1.4 kg, p<0.0007).

In an open-label, randomized, controlled trial, 695 patients with type 2 diabetes mellitus previously treated with oral antidiabetic agents were randomized to treatment with morning insulin glargine, bedtime NPH insulin, or bedtime insulin glargine for 24 weeks in addition to 3 mg of glimepiride.¹²¹ HbA_{1c} levels improved by -1.24 percent with morning insulin glargine, -0.96 percent with bedtime insulin glargine, and -0.84 percent with bedtime NPH insulin. HbA_{1c} improvement was more pronounced with morning insulin glargine than with NPH insulin (p=0.001) or bedtime insulin glargine (p=0.008). Baseline to endpoint fasting blood glucose levels improved similarly in all three groups. Nocturnal hypoglycemia was less frequent with morning (17 percent) and bedtime insulin glargine (23 percent) than with bedtime NPH insulin (38 percent, p<0.001).

In a multicenter, open-label, randomized study, 570 patients with type 2 diabetes were treated with insulin glargine or NPH insulin given once daily at bedtime.¹²² Previous oral antidiabetic therapy was continued throughout the study. At 52 weeks, there was a trend toward a decrease in HbA_{1c} values from baseline to endpoint with both drugs (insulin glargine: -0.46 percent; NPH insulin: -0.38 percent; p=0.415). Over the entire treatment period, NPH insulin-treated patients (41 percent) and insulin glargine-treated patients (35 percent) experienced a similar level of symptomatic hypoglycemia, but there was a statistically significant difference in nocturnal hypoglycemia in NPH patients compared with those treated with insulin glargine in the overall population (24 versus 12 percent, p=0.002). The incidence of adverse events was similar for the two treatments.

Glycemic control and symptomatic hypoglycemia rates with insulin glargine versus NPH were studied in 125 poorly controlled type 1 diabetes patients.¹²³ Patients received preprandial insulin lispro and either insulin glargine or NPH at bedtime for 30 weeks in a randomized, single-blinded fashion. Basal insulin dosage was titrated to achieve FBG values under 5.5 mmol/L. At endpoint, mean HbA_{1c} was 8.3 versus 9.1 percent for the insulin glargine versus NPH groups, but HbA_{1c} was lower in the insulin glargine versus NPH group at study initiation (9.2 versus 9.7 percent). Adjusted least-squares mean change from baseline was -1.04 versus -0.51 percent, a significant treatment benefit in favor of insulin glargine (p<0.01). The mean values for end-point FBG were 7.9 versus 9.0 mmol/L in favor of insulin glargine (p<0.05). Significantly fewer moderate or severe nocturnal hypoglycemic episodes were observed in the insulin glargine group (p=0.04 and p=0.02).

An open-label, 24-week, randomized study compared the efficacy and safety of insulin glargine and insulin NPH, both in combination with a daily fixed dose of glimepiride, in terms of glycemic control and incidence of hypoglycemia.¹²⁴ Patients with poorly controlled type 2 diabetes on oral antidiabetic agents (HbA_{1c} 7.5 to 10.5 percent) received glimepiride plus insulin glargine (n=231) or insulin NPH (n=250) using a forced titration algorithm. Insulin glargine and insulin NPH achieved similar HbA_{1c} reductions. Confirmed nocturnal hypoglycemia was significantly lower with insulin glargine versus insulin NPH (16.9 versus 30 percent; p<0.01).

insulin glargine (Lantus) and human insulin 70/30

In a 24-week, multinational, multicenter, open-label, parallel-group clinical trial, 371 insulin-naïve patients with poor glycemic control on a sulfonylurea plus metformin were randomized to daily morning insulin glargine plus glimepiride and metformin or to insulin 70/30 twice daily without oral antidiabetic agents.¹²⁵ Mean HbA_{1c} decrease from baseline was significantly more pronounced (-1.64 versus -1.31 percent, p=0.0003), and more patients reached HbA_{1c} less than 7 percent without confirmed nocturnal hypoglycemia (45.5 versus 28.6 percent, p=0.0013) with the insulin glargine arm than with insulin 70/30. Similarly, FBG decrease was greater in the

insulin glargine group (adjusted mean difference -17 mg/dL; $p < 0.0001$), and more patients reached target FBG under 100 mg/dL with insulin glargine than with insulin 70/30 (31.6 versus 15 percent, $p = 0.0001$). Insulin glargine patients had fewer confirmed hypoglycemic episodes than insulin 70/30 patients (4.07 versus 9.87 episodes/patient-year, $p < 0.0001$).

insulin glargine (Lantus) and insulin detemir (Levemir)

In a 52-week multinational, open-label, parallel-group, treat-to-target, non-inferiority trial 443 patients with type 1 diabetes and a mean age of 42 years; a mean body mass index of 26.5; a mean HbA_{1c} of 8.1 percent and a mean duration of diabetes of 17.2 years were randomized to receive either insulin detemir or insulin glargine for 52 weeks.¹²⁶ Insulin aspart was administered in both groups as the mealtime insulin. The basal insulin was initially administered once daily in the evening for both groups. If patients in the insulin detemir group achieved target plasma glucose levels before breakfast but not before dinner, administration was changed to twice a day. Insulin glargine patients continued with once daily administration throughout the trial. The primary efficacy endpoint was HbA_{1c} after 52 weeks while the secondary endpoints included the number of patients achieving an HbA_{1c} level less than or equal to 7 percent with or without a major hypoglycemic episode in the last month of treatment. Results after 52 weeks showed no significant differences in mean HbA_{1c} between insulin detemir and insulin glargine groups (7.57 and 7.56 percent, respectively; mean difference, 0.01%; 95% CI, -0.13 to 0.16). Additionally, there was no significant difference in the proportion of patients receiving insulin detemir and insulin glargine in achieving an HbA_{1c} value equal to or lower than 7 percent without major hypoglycemia (31.9 and 28.9 percent, respectively). The relative risks for total and nocturnal hypoglycemia were not significantly different between insulin detemir and insulin glargine (0.94 and 1.12, respectively; $p = \text{NS}$).

insulin glargine (Lantus), insulin detemir (Levemir), and insulin aspart (Novolog)

In a 26-week, multicenter, open-label, parallel-group trial, 320 type 1 diabetics received either insulin detemir twice daily or insulin glargine once daily, each in combination with premeal insulin aspart.¹²⁷ After 26 weeks, HbA_{1c} decreased from 8.8 to 8.2 percent in the insulin detemir group and from 8.7 to 8.2 percent in the insulin glargine group. The overall risk of hypoglycemia was similar; however, the risk of severe and nocturnal hypoglycemia was 72 and 32 percent lower, respectively, with insulin detemir than with insulin glargine ($p < 0.05$). Body weight gain was not significantly different between treatment arms.

insulin glargine (Lantus) and biphasic insulin aspart (Novolog Mix 70/30)

The 28-week parallel-group study randomized 233 insulin-naive patients on more than 1,000 mg daily with metformin alone or in combination with other oral antidiabetic agents to receive biphasic insulin aspart twice daily or insulin glargine at bedtime and titrated to target blood glucose.¹²⁸ At study end, the mean HbA_{1c} value was lower in the biphasic insulin aspart group than in the insulin glargine group (6.91 versus 7.41 percent, $p < 0.01$). The HbA_{1c} reduction was greater in the biphasic insulin aspart group than in the insulin glargine group (-2.79 versus -2.36 percent, $p < 0.01$), especially for subjects with baseline HbA_{1c} greater than 8.5 percent ($p < 0.05$). Minor hypoglycemia was greater in the biphasic insulin aspart group than in the insulin glargine group (3.4 and 0.7 episodes/year; $p < 0.05$), and weight gain at study end was greater for biphasic insulin aspart-treated subjects than for insulin glargine-treated subjects (5.4 versus 3.5 kg, $p < 0.01$).

In the randomized, open-label, parallel study, biphasic insulin aspart plus metformin twice daily were compared with insulin glargine plus glimepiride daily in 255 insulin-naïve patients.¹²⁹ The primary endpoint was the difference in absolute change in HbA_{1c} between groups after 26 weeks of treatment. HbA_{1c} change was significantly greater in the insulin aspart group than the insulin glargine group (between-group difference: -0.5 percent; p=0.0002). During the maintenance phase, one major hypoglycemic episode occurred in each group; 20.3 and 9 percent of patients experienced minor hypoglycemic episodes in the insulin aspart and insulin glargine groups, respectively (p=0.0124). Insulin glargine patients experienced significant weight gain of 1.5 kg (p<0.0001); the weight change with insulin aspart patients of +0.7 kg was not statistically significant (p=0.0762).

In a 26-week, open-labeled, randomized, parallel-group, multinational, treat-to-target trial, 480 insulin-naïve type 2 patients with diabetes with inadequate control on oral anti-diabetic medications were randomized to receive either biphasic insulin aspart prior to dinner or insulin glargine at bedtime in combination with metformin and glimepiride.¹³⁰ A total of 433 patients completed the trial. At the end of treatment, biphasic insulin aspart and insulin glargine reduced the mean HbA_{1c} levels by -1.41 percent and 1.25 percent, respectively (95% CI, -0.3 to -0.02; p=0.029). After 26 weeks, the mean HbA_{1c} levels were 7.1 percent for the biphasic insulin aspart group and 7.3 percent for the insulin glargine group. The relative risk for a nocturnal hypoglycemic episode was greater in the biphasic insulin aspart group than for insulin glargine (relative risk: 2.41; 95%CI, 1.34 to 4.34; p=0.003), although hypoglycemic rates were overall low with three major episodes occurring in each group.

insulin glargine (Lantus) and insulin lispro (Humalog)

In an open-label, multicenter study, 418 patients with type 2 diabetes inadequately controlled with oral hypoglycemic agents were randomized to receive either insulin glargine administered once daily (n=205) or insulin lispro administered three times daily (n=210).¹³¹ The primary efficacy endpoint was the change in HbA_{1c} from baseline to endpoint (week 44). There was no significant difference between the two treatment groups relative to mean reduction in HbA_{1c} or in the number of patients who achieved a HbA_{1c} of 7 percent or less. However, the mean change in fasting blood glucose was significantly greater in the insulin glargine group (-4.3 mmol/L) compared to the insulin lispro group (-1.8 mmol/L; p<0.0001). Patients treated with insulin glargine were also shown to have greater reductions in nocturnal blood glucose compared with patients treated with insulin lispro (-3.3 mmol/L versus -2.6 mmol/L; p=0.0041). Hypoglycemic episodes occurred at a rate of 5.2 events per patient per year for insulin glargine and 24.0 events per patient per year for insulin lispro (p<0.001). There was no significant difference in mean weight gain between the two treatment groups.

insulin glargine (Lantus) and biphasic insulin lispro (Humalog Mix)

Type 2 diabetics (n=374) were randomly assigned to insulin lispro mix 50/50 three times daily with meals or insulin glargine at bedtime plus mealtime insulin lispro in a 24-week, multicenter, open-label, no inferiority trial.¹³² Investigators could replace insulin lispro mix 50/50 with 75/25 at the evening meal if the fasting plasma glucose target was unachievable. At week 24, HbA_{1c} was lower with insulin glargine (6.78 versus 6.95 percent, p=0.021), but HbA_{1c} was reduced significantly from baseline for both therapies (p<0.0001). Noninferiority of insulin lispro mix to insulin glargine was not demonstrated based on the prespecified noninferiority margin of 0.3 percent. The percentages of patients achieving target HbA_{1c} varied depending on the specific target; statistically significant differences did occur in favor of insulin glargine at HbA_{1c}<7 percent and HbA_{1c}<6.5 percent. Rates of hypoglycemia were similar for both groups.

insulin glulisine (Apidra) and regular human insulin

Patients with type 1 diabetes (n=860) received daily insulin glargine and were randomized to either insulin glulisine injected within 15 minutes before or immediately after meals or regular human insulin, injected 30 to 45 minutes before meals in the open-label, controlled, multicenter, parallel-group, 12-week study.¹³³ Changes in mean HbA_{1c} were -0.26, -0.11, and -0.13 percent in the pre-meal insulin glulisine, post-meal insulin glulisine, and regular insulin groups, respectively. The reduction in HbA_{1c} was greater for the pre-meal insulin glulisine group in comparison with the regular insulin group (p=0.02) and the post-meal insulin glulisine group (p=0.006); no significant difference was found between post-meal insulin glulisine versus regular insulin. Overall, blood glucose profiles were similar in all three treatment groups but were significantly lower for pre-meal insulin glulisine post-breakfast and post-dinner measurements. Severe hypoglycemic episodes were comparable for all groups. Body weight increased (+0.3 kg) in the regular insulin and pre-meal insulin glulisine groups; however, weight decreased in the post-meal insulin glulisine group (-0.3 kg; p=0.03).

Patients with type 2 diabetes who had received at least six months of continuous insulin therapy were randomized in a multinational, controlled, open-label, parallel group, 26-week study.¹³⁴ Patients (n=890) received NPH insulin twice daily and either insulin glulisine or regular insulin at least twice daily. There were no differences in HbA_{1c} reductions (insulin glulisine: -0.32 percent; regular insulin: -0.35 percent; p=0.57). Insulin glulisine lowered plasma glucose significantly more versus regular insulin at two hours (14.14 mmol/L versus 15.28 mmol/L; p=0.0025). Nocturnal hypoglycemia from the fourth month to the end of treatment was less frequent with insulin glulisine versus regular insulin (9.1 versus 14.5 percent; p=0.029).

insulin glulisine (Apidra) and insulin lispro (Humalog)

The objective of the multinational, multicenter, controlled, open-label, randomized, parallel-group study was to compare the efficacy and safety of insulin glulisine to that of insulin lispro in adults diagnosed with type 1 diabetes.¹³⁵ Of the 683 patients randomized, 672 received treatment. Over the 26-week study, a similar reduction in mean HbA_{1c} occurred in both groups (adjusted mean change from baseline -0.14 percent in both groups). The basal insulin dose was relatively unchanged from baseline in the insulin glulisine group but increased in the insulin lispro group (insulin glulisine: 0.12 units versus insulin lispro: 1.82 units; p=0.0001). There was no relevant difference between the two groups in the reporting of symptomatic hypoglycemia (overall, nocturnal, or severe).

insulin lispro (Humalog) and regular human insulin

In a 5.5-month randomized, open-label, parallel study of 148 patients with type 2 diabetes receiving either insulin lispro (n=70) or regular human insulin (n=78), eight-point blood glucose profiles and HbA_{1c} measurements were collected at baseline, 1.5, 3.5, and 5.5 months.¹³⁶ Two-hour post-breakfast and two-hour post-supper blood glucose levels were significantly lower for insulin lispro than for regular human insulin at the end point (p=0.02 in both cases). HbA_{1c} improved from 10.5 percent (insulin lispro) and 10.3 percent (regular human insulin) to 8 percent in each treatment arm. Hypoglycemia rates were similar during the day with a trend towards a reduced incidence in the night hours with insulin lispro (0.08 episodes/month versus 0.16 episodes/month, p=0.057).

Meta-Analyses

A systematic review of 45 studies was performed to compare premixed insulin analogues with any other antidiabetic agents for the treatment of type 2 diabetes in adults.¹³⁷ The outcomes examined included fasting glucose, postprandial glucose, HbA_{1c}, and weight gain. Mortality data are scant. Of the 45 studies, 43 were randomized controlled trials. The studies included a total of 14,603 patients with a mean age of 59 years, a median HbA_{1c} of 8.7 percent, and a mean body mass index (BMI) of 29.4 kg/m². When compared with long-acting insulin analogues, premixed insulin analogues were found to be more effective in reducing postprandial glucose levels (pooled difference, -27.9 mg/dL; CI, -34.3 to -21.5 mg/dL) and HbA_{1c} (pooled difference, -0.39%; CI, -0.5% to -0.3%). However, premixed insulin analogues were found to be less effective than long-acting insulin analogues in reducing fasting glucose levels (pooled difference, 12.0 mg/dL; CI, 6.0 to 18.1 mg/dL). Premixed insulin analogues were also associated with an increased incidence of hypoglycemia (OR, 2.0 [CI, 1.3 to 3.0]) and weight gain (pooled difference, 2.0 kg [CI, 1.1 to 3.0 kg]) compared with long-acting insulins. Premixed insulin analogues were similar to premixed human insulin in decreasing fasting glucose levels, HbA_{1c} levels, and the incidence of hypoglycemia but were more effective in decreasing postprandial glucose levels (mean difference, 21.1 mmol/L; 95% CI, 21.4 to 20.7 mmol/L [219.2 mg/dL; 95% CI, 225.9 to 212.5 mg/dL]). Compared to other non-insulin anti-diabetic agents, premixed insulin analogues were more effective in decreasing fasting glucose levels, postprandial glucose levels and HbA_{1c} levels, but were associated with a higher incidence of hypoglycemia.

Summary

Human insulin products (Humulin and Novolin), produced by recombinant DNA technology, contain the exact same insulin amino acids and have the same action as endogenous insulin. Depending on the composition of the product, the onset, peak, and duration of activity can vary, but the effects of these products on HbA_{1c}, FPG, and hypoglycemia are very similar.

Insulin aspart (Novolog), insulin glulisine (Apidra), and insulin lispro (Humalog) are insulin products that have a faster onset of activity and shorter duration of action than human insulin. Insulin aspart and insulin lispro have been shown to decrease HbA_{1c} by an additional 0.1-0.2 percent, decrease the incidence of hypoglycemia episodes by about 20 percent, decrease nocturnal hypoglycemic episodes by 25-50 percent, and decrease FPG levels compared to human insulins. Insulin glulisine studies show an additional decrease in HbA_{1c} of about 0.1 percent, as well. All of these products may be administered with a meal rather than the 30 to 60 minutes prior to a meal for regular human insulin. Insulin aspart vials and cartridges are latex-free, and the solution contains less cresol than insulin lispro, as does insulin glulisine. All of the rapid-acting insulins are approved for use in pediatric patients as well as for use in external insulin pumps. All are also available in cartridge and pen delivery systems.

The biphasic insulins (Humalog Mix 50/50 and 75/25, Novolog Mix 70/30, and human insulin 70/30) combine both a fast-acting and a long-acting insulin. Their purpose is to decrease the number of injections needed per day for a diabetic patient. Both insulin lispro and insulin aspart combinations have a faster onset of activity and shorter duration of action than biphasic human insulin. Insulin glulisine is not available in such a combination.

Insulin detemir (Levemir) and insulin glargine (Lantus) have changes in the amino acid sequence. They produce a longer duration of action with minimal peak effect and are used as

basal insulins. Both may be used in type 1 diabetics as a basal insulin, and in combination with oral antidiabetic medications in type 2 diabetics. Each agent consistently controls glycemic levels better than insulin NPH, with less hypoglycemia. Compared to human insulin, these agents decrease episodes of hypoglycemia by 25-50 percent, decrease nocturnal hypoglycemic episodes by 25-33 percent, and generally have lower FPG levels. Effects on HbA_{1c} are comparable with human insulin.

References

- ¹ Humulin [package insert]. Indianapolis, IN; Eli Lilly; September 2009.
- ² Novolin [package insert]. Princeton, NJ; Novo Nordisk; June 2009.
- ³ Novolog [package insert]. Princeton, NJ; Novo Nordisk; July 2009.
- ⁴ Apidra [package insert]. Kansas City, MO; Aventis Pharmaceuticals; February 2009.
- ⁵ Humalog [package insert]. Indianapolis, IN; Eli Lilly; September 2009.
- ⁶ Levemir [package insert]. Princeton, NJ; Novo Nordisk; July 2009.
- ⁷ Lantus [package insert]. Kansas City, MO; Aventis Pharmaceuticals; June 2009.
- ⁸ Novolog Mix 70/30 [package insert]. Princeton, NJ; Novo Nordisk; October 2009.
- ⁹ Humalog Mix 75/25 [package insert]. Indianapolis, IN; Eli Lilly; March 2009.
- ¹⁰ Humalog Mix 50/50 [package insert]. Indianapolis, IN; Eli Lilly; March 2009.
- ¹¹ Diabetes Statistics. <http://www.diabetes.org/diabetes-basics/diabetes-statistics/>. Accessed March 15, 2010.
- ¹² Skyler JS. Glucose control in type 2 diabetes mellitus. *Ann Intern Med.* 1997; 127:837-839.
- ¹³ American Diabetes Association. Standards of Medical Care in Diabetes-2009. *Diabetes Care.* 2010; 33(Suppl 1):S11-61.
- ¹⁴ Nathan DM, Buse JB, Davidson MB, et al. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. *Diabetes Care.* 2009, 32(1):193-203.
- ¹⁵ American Diabetes Association. Standards of Medical Care in Diabetes-2009. *Diabetes Care.* 2009; 32(Suppl 1):S13-61.
- ¹⁶ American Diabetes Association. Standards of Medical Care in Diabetes-2009. *Diabetes Care.* 2010; 33(Suppl 1):S11-61.
- ¹⁷ Rodbard HW, Blonde L, Braithwaite SS, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Management of Diabetes Mellitus. *Endocr Pract.* 2007; 13(1):4-68.
- ¹⁸ Humulin [package insert]. Indianapolis, IN; Eli Lilly; September 2009..
- ¹⁹ Novolin [package insert]. Princeton, NJ; Novo Nordisk; June 2009
- ²⁰ Novolog [package insert]. Princeton, NJ; Novo Nordisk; July 2009.
- ²¹ Apidra [package insert]. Kansas City, MO; Aventis Pharmaceuticals; February 2009.
- ²² Humalog [package insert]. Indianapolis, IN; Eli Lilly; September 2009.
- ²³ Novolog Mix70/30 [package insert]. Princeton, NJ; Novo Nordisk; October 2009.
- ²⁴ Humalog Mix 75/25 [package insert]. Indianapolis, IN; Eli Lilly; March 2009.
- ²⁵ Humalog Mix 50/50 [package insert]. Indianapolis, IN; Eli Lilly; March 2009.
- ²⁶ Humulin [package insert]. Indianapolis, IN; Eli Lilly; September 2009.
- ²⁷ Novolin [package insert]. Princeton, NJ; Novo Nordisk; June 2009.
- ²⁸ Levemir [package insert]. Princeton, NJ; Novo Nordisk; July 2009.
- ²⁹ Plank J, Bodenlenz M, Sinner F, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. *Diabetes Care.* 2005; 28(5):1107-12.
- ³⁰ Lantus [package insert]. Kansas City, MO; Aventis Pharmaceuticals; June 2009.
- ³¹ Humulin [package insert]. Indianapolis, IN; Eli Lilly; September 2009.
- ³² Novolin [package insert]. Princeton, NJ; Novo Nordisk; June 2009.
- ³³ Novolog [package insert]. Princeton, NJ; Novo Nordisk; October 2009.
- ³⁴ Apidra [package insert]. Kansas City, MO; Aventis Pharmaceuticals; February 2009.
- ³⁵ Humalog [package insert]. Indianapolis, IN; Eli Lilly; September 2009.
- ³⁶ Levemir [package insert]. Princeton, NJ; Novo Nordisk; July 2009.
- ³⁷ Lantus [package insert]. Kansas City, MO; Aventis Pharmaceuticals; June 2009.
- ³⁸ Novolog Mix 70/30 [package insert]. Princeton, NJ; Novo Nordisk; July 2009.
- ³⁹ Humalog Mix 75/25 [package insert]. Indianapolis, IN; Eli Lilly; March 2009.
- ⁴⁰ Humalog Mix 50/50 [package insert]. Indianapolis, IN; Eli Lilly; March 2009.
- ⁴¹ Humulin [package insert]. Indianapolis, IN; Eli Lilly; September 2009.
- ⁴² Novolin [package insert]. Princeton, NJ; Novo Nordisk; June 2009.
- ⁴³ Novolog [package insert]. Princeton, NJ; Novo Nordisk; October 2009.
- ⁴⁴ Apidra [package insert]. Kansas City, MO; Aventis Pharmaceuticals; February 2009.
- ⁴⁵ Humalog [package insert]. Indianapolis, IN; Eli Lilly; September 2009.
- ⁴⁶ Levemir [package insert]. Princeton, NJ; Novo Nordisk; July 2009.
- ⁴⁷ Lantus [package insert]. Kansas City, MO; Aventis Pharmaceuticals; June 2009.
- ⁴⁸ Novolog Mix 70/30 [package insert]. Princeton, NJ; Novo Nordisk; July 2009.
- ⁴⁹ Humalog Mix 75/25 [package insert]. Indianapolis, IN; Eli Lilly; March 2009.
- ⁵⁰ Humalog Mix 50/50 [package insert]. Indianapolis, IN; Eli Lilly; March 2009.
- ⁵¹ Humulin [package insert]. Indianapolis, IN; Eli Lilly; September 2009.
- ⁵² Novolin [package insert]. Princeton, NJ; Novo Nordisk; June 2009.
- ⁵³ Novolog [package insert]. Princeton, NJ; Novo Nordisk; October 2009.

- ⁵⁴ Apidra [package insert]. Kansas City, MO; Aventis Pharmaceuticals; February 2009.
- ⁵⁵ Humalog [package insert]. Indianapolis, IN; Eli Lilly; September 2009.
- ⁵⁶ Levemir [package insert]. Princeton, NJ; Novo Nordisk; July 2009.
- ⁵⁷ Lantus [package insert]. Kansas City, MO; Aventis Pharmaceuticals; June 2009.
- ⁵⁸ Novolog Mix 70/30 [package insert]. Princeton, NJ; Novo Nordisk; July 2009.
- ⁵⁹ Humalog Mix 75/25 [package insert]. Indianapolis, IN; Eli Lilly; March 2009.
- ⁶⁰ Humalog Mix 50/50 [package insert]. Indianapolis, IN; Eli Lilly; March 2009.
- ⁶¹ Humulin [package insert]. Indianapolis, IN; Eli Lilly; September 2009.
- ⁶² Novolin [package insert]. Princeton, NJ; Novo Nordisk; June 2009.
- ⁶³ Novolog [package insert]. Princeton, NJ; Novo Nordisk; October 2009.
- ⁶⁴ Apidra [package insert]. Kansas City, MO; Aventis Pharmaceuticals; February 2009.
- ⁶⁵ Humalog [package insert]. Indianapolis, IN; Eli Lilly; September 2009.
- ⁶⁶ Levemir [package insert]. Princeton, NJ; Novo Nordisk; July 2009.
- ⁶⁷ Lantus [package insert]. Kansas City, MO; Aventis Pharmaceuticals; June 2009.
- ⁶⁸ Novolog Mix 70/30 [package insert]. Princeton, NJ; Novo Nordisk; July 2009.
- ⁶⁹ Humalog Mix 75/25 [package insert]. Indianapolis, IN; Eli Lilly; March 2009.
- ⁷⁰ Humalog Mix 50/50 [package insert]. Indianapolis, IN; Eli Lilly; March 2009.
- ⁷¹ Schober E, Schoenle E, Van Dyk J, et al. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. *J Pediatr Endocrinol Metab.* 2002; 15(4):369-376.
- ⁷² Mortensen H, Kocova M, Teng LY, et al. Biphasic insulin aspart versus human insulin in adolescents with type 1 diabetes on multiple daily insulin injections. *Pediatr Diabetes.* 2006; 7(1):4-10.
- ⁷³ Robertson KJ, Schoenle E, Gucev Z, et al. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes. *Diabet Med.* 2007; 24(1):27-34.
- ⁷⁴ Apidra [package insert]. Kansas City, MO; Aventis Pharmaceuticals; February 2009.
- ⁷⁵ Mathiesen ER, Kinsley B, Amiel SA, et al. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. *Diabetes Care.* 2007; 30(4):771-776.
- ⁷⁶ Pan CY, Sinnassamy P, Chung KD, et al. Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients. *Diabetes Res Clin Pract.* 2007; 76(1):111-118.
- ⁷⁷ Hirao K, Arai K, Yamauchi M, et al. Six-month multicenter, open-label, randomized trial of twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart in Japanese type 2 diabetic patients (JDDM 11). *Diabetes Res Clin Pract.* 2008; 79(1):171-176.
- ⁷⁸ Bebakar WM, Chow CC, Kadir KA, et al. Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes. *Diabetes Obes Metab.* 2007; 9(5):724-732.
- ⁷⁹ Humulin [package insert]. Indianapolis, IN; Eli Lilly; September 2009.
- ⁸⁰ Novolin [package insert]. Princeton, NJ; Novo Nordisk; June 2009.
- ⁸¹ Novolog [package insert]. Princeton, NJ; Novo Nordisk; October 2009.
- ⁸² Apidra [package insert]. Kansas City, MO; Aventis Pharmaceuticals; February 2009.
- ⁸³ Humalog [package insert]. Indianapolis, IN; Eli Lilly; September 2009.
- ⁸⁴ Levemir [package insert]. Princeton, NJ; Novo Nordisk; July 2009.
- ⁸⁵ Lantus [package insert]. Kansas City, MO; Aventis Pharmaceuticals; June 2009.
- ⁸⁶ Novolog Mix 70/30 [package insert]. Princeton, NJ; Novo Nordisk; July 2009.
- ⁸⁷ Humalog Mix 75/25 [package insert]. Indianapolis, IN; Eli Lilly; March 2009.
- ⁸⁸ Humalog Mix 50/50 [package insert]. Indianapolis, IN; Eli Lilly; March 2009.
- ⁸⁹ Available at: <http://www.novonordiskcare.com/flexpen-insulins>. Accessed on March 13, 2010.
- ⁹⁰ Available at: http://insidehumalog.com/hcp/insulin_pens.jsp. Accessed on March 13, 2010.
- ⁹¹ Available at: <http://www.novonordisk.com/diabetes/public/insulinpens/novopenjunior/default.asp>. Accessed on March 13, 2010.
- ⁹² Available at: http://www.lantus.com/solostar/solostar_pen_at_a_glance.aspx. Accessed on March 13, 2010.
- ⁹³ Available at: <http://www.apidra.com/>. Accessed on March 13, 2010.
- ⁹⁴ Available at: http://insidehumalog.com/hcp/insulin_pens.jsp. Accessed on March 13, 2010.
- ⁹⁵ Tamas G, Marre M, Astorga R, et al. Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study. *Diabetes Res Clin Pract.* 2001; 54(2):105-114.
- ⁹⁶ Home RD, Lindholm A, Riis A. Insulin aspart versus human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial. *Diabet Med.* 2000 ;17:762-770.
- ⁹⁷ Raskin P, Guthrie RA, Leiter L, et al. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. *Diabetes Care.* 2000; 23(5):583-588.
- ⁹⁸ DeVries JH, Lindholm A, Jacobsen JL, et al. A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with Type 1 diabetes. *Diabet Med.* 2003; 20(4):312-8.
- ⁹⁹ Bott U, Ebrahim S, Hirschberger S, et al. Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with Type 1 diabetes. *Diabet Med.* 2003; 20(8):626-634.
- ¹⁰⁰ Heller SR, Colagiuri S, Vaaler S, et al. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes. *Diabet Med.* 2004; 21(7):769-775.
- ¹⁰¹ Bretzel RG, Arnolds S, Medding J, et al. A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes. *Diabetes Care.* 2004; 27(5):1023-1027.
- ¹⁰² Abrahamian H, Ludvik B, Scherthner G, et al. Improvement of glucose tolerance in type 2 diabetic patients: traditional versus modern insulin regimens (results from the Austrian Biaspart Study). *Horm Metab Res.* 2005; 37(11):684-689.
- ¹⁰³ Christiansen JS, Vaz JA, Metelko Z, et al. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes. *Diabetes Obes Metab.* 2003; 5(6):446-454.

- ¹⁰⁴ Niskanen L, Jensen LE, Rastam J, et al. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. *Clin Ther.* 2004; 26(4):531-540.
- ¹⁰⁵ Russell-Jones D, Simpson R, Hylleberg B, et al. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type 1 diabetes mellitus using a basal-bolus regimen. *Clin Ther.* 2004; 26(5):724-736.
- ¹⁰⁶ Philis-Tsimikas A, Charpentier G, Clauson P, et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. *Clin Ther.* 2006; 28(10):1569-1581.
- ¹⁰⁷ Hermansen K, Davies M, Dereziński T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. *Diabetes Care.* 2006; 29(6):1269-1274.
- ¹⁰⁸ Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. *N Engl J Med.* 2007; 357(17):1716-30.
- ¹⁰⁹ Vague P, Selam JL, Skeie S, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. *Diabetes Care.* 2003; 26(3):590-596.
- ¹¹⁰ Home P, Bartley P, Russell-Jones D, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. *Diabetes Care.* 2004; 27(5):1081-1087.
- ¹¹¹ Haak T, Tiengo A, Draeger E, et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. *Diabetes Obes Metab.* 2005; 7(1):56-64.
- ¹¹² Pieber TR, Draeger E, Kristensen A, et al. Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir versus morning plus bedtime NPH insulin. *Diabet Med.* 2005; 22(7):850-857.
- ¹¹³ Hermansen K, Fontaine P, Kukolja KK, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. *Diabetologia.* 2004; 47(4):622-629.
- ¹¹⁴ Raslova K, Bogoev M, Raz I, et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. *Diabetes Res Clin Pract.* 2004; 66(2):193-201.
- ¹¹⁵ Raskin P. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. *Diabetes Care.* 2000; 23(11):1666-1671.
- ¹¹⁶ Ratner RE, Hirsch IB, Neifing JL, et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. *Diabetes Care.* 2000; 23(5):639-643.
- ¹¹⁷ Hershon KS et al. Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetes. *Endocr Pract.* 2004; 10(1):10-17.
- ¹¹⁸ Porcellati F, Rossetti P, Pampanelli S, et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin. *Diabet Med.* 2004; 21(11):1213-1220.
- ¹¹⁹ Riddle MC, Rosenstock J, Gerich J, et al. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. *Diabetes Care.* 2003; 26(11):3080-3086.
- ¹²⁰ Rosenstock J, Schwartz SL, Clark CM Jr, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. *Diabetes Care.* 2001; 24(4):631-636.
- ¹²¹ Fritsche A, Schweitzer MA, Haring HU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. *Ann Intern Med.* 2003; 138(12):952-959.
- ¹²² Massi Benedetti M, Humburg E, Dressler A, et al. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. *Horm Metab Res.* 2003; 35(3):189-196.
- ¹²³ Fulcher GR, Gilbert RE, Yue DK. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. *Intern Med J.* 2005; 35(9):536-542.
- ¹²⁴ Eliaschewitz FG, Calvo C, Valbuena H, et al. Therapy in type 2 diabetes: insulin glargine versus NPH insulin both in combination with glimepiride. *Arch Med Res.* 2006; 37(4):495-501.
- ¹²⁵ Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. *Diabetes Care.* 2005; 28(2):254-259.
- ¹²⁶ Heller S, Koenen C, Bode B. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial. *Clin Ther.* 2009; 31(10):2086-97.
- ¹²⁷ Pieber TR, Treichel HC, Hompesch B, et al. Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy. *Diabet Med.* 2007; 24(6):635-642.
- ¹²⁸ Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. *Diabetes Care.* 2005; 28(2):260-265.
- ¹²⁹ Kann PH, Wascher T, Zackova V, et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. *Exp Clin Endocrinol Diabetes.* 2006; 114(9):527-532.
- ¹³⁰ Strojek K, Bebakar WM, Khutsoane DT, et al. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational. RCT. *Curr Med Res Opin.* 2009; 25(12):2887-94.
- ¹³¹ Bretzel RG, Nuber U, Landgraf W, et al. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomized controlled trial. *Lancet.* 2008; 371(9618):1073-84.
- ¹³² Rosenstock J, Ahmann AJ, Colon G, et al. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. *Diabetes Care.* 2008; 31(1):20-25.
- ¹³³ Garg SK, Rosenstock J, Ways K. Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine. *Endocr Pract.* 2005; 11(1):11-17.

¹³⁴ Rayman G, Profozic V, Middle M. Insulin glulisine imparts effective glycaemic control in patients with Type 2 diabetes. *Diabetes Res Clin Pract.* 2007; 76(2):304-312.

¹³⁵ Dreyer M, Prager R, Robinson A, et al. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. *Horm Metab Res.* 2005; 37(11):702-707.

¹³⁶ Ross SA, Zinman B, Campos RV, et al. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. *Clin Invest Med.* 2001; 24(6):292-8.

¹³⁷ Qayyum R, Bolen S, Maruthur N, et al. Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. *Ann Intern Med.* 2008; 149.